Advertisement

PharmacoEconomics & Outcomes News

, Volume 836, Issue 1, pp 18–18 | Cite as

Nivolumab in resected melanoma: clinical benefits at lower cost

Clinical study
  • 4 Downloads

Reference

  1. Freeman M, et al. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data. Advances in Therapy : 22 Aug 2019. Available from: URL: http://doi.org/10.1007/s12325-019-01060-y

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations